- Shares of AcelRx (ACRX +9.6%) move sharply higher on heavy volume.
- Perhaps helping the cause is an article from SA contributor Stock Matusow who points to a Sufentanil Nanotab NDA as a near-term catalyst.
- Matusow also likes the company's cash position and isn't shy about the possibility of a takeout: "Based on the rumors we have heard, and comparing these rumors to the past performance of BOD members, we believe the company will be acquired within six months."
AcelRx jumps, Seeking Alpha contributor predicts buyout
Sep 20 2013, 11:46 ET